[{"id":"e2e18e0d-d872-46fc-9331-6fc0c0e97f5b","acronym":"IMMCO-1","url":"https://clinicaltrials.gov/study/NCT05000294","created_at":"2021-08-11T14:55:29.843Z","updated_at":"2024-07-02T16:35:14.403Z","phase":"Phase 1/2","brief_title":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","source_id_and_acronym":"NCT05000294 - IMMCO-1","lead_sponsor":"University of Florida","biomarkers":" HER-2 • TMB • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HR negative + HER-2 positive","tags":["HER-2 • TMB • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HR negative + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Fotivda (tivozanib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-15"}]